Past performance does not predict future results. Informational only, not investment advice.
ATOS trades near cash value with a clinical catalyst (Karisma 24-month durability data expected Q3 2026) that could drive a re-rate and improve funding terms. Chart setup shows a base forming with potential upside to the 200-day SMA if price breaks above 2.80.
ATOS will experience significant forced buying from R2K index funds (10-20M shares on June 25) combined with an extraordinary gamma squeeze from 499K July call contracts representing 23% of shares outstanding. Catalysts include institutional accumulation, options-driven MM buying into July expiry, short covering, and fundamental updates on the Endoxifen drug program, all expected to drive substantial upside.
ATOS is a biotech with asymmetric upside similar to meme stocks: $138M in cash (no debt, runway to 2024), trades at $1.78/share ex-cash, and will cross the $1B market cap threshold at ~$8.50/share, triggering passive buying and institutional inclusion. With Endoxifen targeting 68% of breast cancers, long-term valuations of $33–$175/share are possible; gamma and short squeeze dynamics add near-term catalysts.
Atossa Therapeutics is developing three promising pipeline products: AT-301 (COVID-19 nasal spray completing Phase 1), AT-H201 (COVID-19 therapeutic with potential for faster development than vaccines), and oral endoxifen (addressing metabolic gaps in the most-prescribed breast cancer SERM). The author holds 22,500 shares and sees multiple near-term catalysts from FDA interactions and clinical progression.
Atossa Therapeutics reported substantially positive Phase 2 results for Endoxifen in breast cancer, with the trial halted early due to success. The poster expects near-term upside following a company conference, viewing early dips as a buying opportunity.
End of results.